宏利上月起推虚拟会面遥距销售 涵盖两款新危疾险
宏利香港公布推出新危疾产品「活耀人生危疾保2」及其加强版,旧有的「活耀人生危疾保」将会下架,不会影响已投保的客户。宏利香港首席产品总监兼康健主管纪荣道表示,假设所有投保条件一样,「活耀人生危疾保2」的保费较「活耀人生危疾保」贵大约2%至3%,产品则新增深切治疗部保障横跨列明及未列明疾病、可获因危疾後严重影响日常生活的额外保障,加强版更有提供癌症治疗每年经济援助。
纪荣道表示,公司上月起已推出虚拟会面遥距销售方案,作为面对面销售以外的另一选择,相关销售方案亦会涵盖新推出的保险产品。他指虚拟会面遥距销售目前反应正面,不过由於推出时间不长,暂时难以作出评估。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.